Related Experiment Video
Updated: Jan 4, 2026
09:31
Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
Published on: November 5, 2016
7.6K
Protective Effects of Konjac and Inulin Extracts on Type 1 and Type 2 Diabetes
Tianle Gao1, Yue Jiao2, Yang Liu2
1State Key Laboratory of Bioactive Substances and Function of Natural Medicine, Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing 100050, China.
Journal of Diabetes Research
|November 6, 2019
Summary
Konjac-inulin (KI) composition effectively manages blood glucose and triglycerides in animal models of type 1 and type 2 diabetes. This dietary supplement shows promise for individuals at risk of diabetes.
Area of Science:
- Metabolic diseases research
- Nutritional science
- Pharmacology
Background:
- Type 1 and type 2 diabetes are significant global health concerns.
- Dietary interventions are crucial for diabetes management.
- Konjac and inulin are known for their potential health benefits.
Purpose of the Study:
- To evaluate the efficacy of konjac-inulin (KI) composition against type 1 and type 2 diabetes.
- To compare the effects of KI composition with konjac extract and inulin extract alone.
- To investigate the impact of KI on key diabetes-related biomarkers.
Main Methods:
- Animal models: Streptozotocin-induced type 1 diabetic rats and db/db mice for type 2 diabetes.
- Treatment groups included vehicle control, varying doses of KI composition, konjac extract, and inulin extract.
- Monitoring of blood glucose, body weight, triglycerides, glycated serum proteins, and insulin expression via immunohistochemistry.
Main Results:
- Daily KI composition significantly reduced blood glucose and triglyceride levels.
- Improved insulin production in islets and reduced obesity were observed in diabetic models.
- KI composition demonstrated superior efficacy compared to konjac or inulin alone.
Conclusions:
- Konjac-inulin (KI) composition exhibits a protective role in both type 1 and type 2 diabetes.
- Provides an experimental basis for developing KI as a dietary supplement for diabetic populations.
- Supports the use of KI for individuals at high risk of developing diabetes.
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
490
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
490
01:23Dipeptidyl Peptidase 4 Inhibitors
525
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
525
01:24Glucagon-like Receptor Agonists
792
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
792
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
547
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
547
01:06Oral Hypoglycemic Agents: Glinides
542
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
542
01:22Diabetes Mellitus: Type 2 and Gestational
4.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.2K